Evidence map›Paper›PMID 30989489›Full record

ArticlePathology oncology research : POR2020

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.

Anna Gasinska, Janusz Jaszczynski, Urszula Rychlik, Elżbieta Łuczynska, Marek Pogodzinski, Mikolaj Palaczynski

Open access · hybridAbstract read
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Prostate Cancer and the Mevalonate Pathway.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Cancer research · 2021
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Anna GasinskaDepartment of Tumour Pathology, Oncology Center, Maria Sklodowska - Curie Institute, Cracow Branch, Garncarska 11, 31-115, Cracow, Poland. z5gasins@cyf-kr.edu.pl.ORCID http://orcid.org/0000-0002-8421-4764
Janusz JaszczynskiDepartment of Surgery, Oncology Center, Maria Sklodowska - Curie Institute, Cracow Branch, Cracow, Poland.
Urszula RychlikDepartment of Clinical Biochemistry, Oncology Center, Maria Sklodowska-Curie Institute, Cracow Branch, Cracow, Poland.
Elżbieta ŁuczynskaDepartment of Radiology, Oncology Center, Maria Sklodowska-Curie Institute, Cracow Branch, Cracow, Poland.
Marek PogodzinskiDepartment of Surgery, Oncology Center, Maria Sklodowska - Curie Institute, Cracow Branch, Cracow, Poland.
Mikolaj PalaczynskiDepartment of Surgery, Oncology Center, Maria Sklodowska - Curie Institute, Cracow Branch, Cracow, Poland.
The Maria Sklodowska-Curie National Research Institute of Oncology · PLNational Institute of Oncology · HU

Funding

Polish Ministry of Science and Higher Education Springer Open Choice
6 · The paper itself

Abstract

The aim of the study was to evaluate prognosis for biochemical recurrence (BR) by analysing the pathological and biological characteristics of prostate cancer (PCa) after radical prostatectomy (RP). There were 130 men with clinically localized PCa in whom pretreatment serum PSA level and Ki-67, prostate specific membrane antigen (PSMA), glucose transporter-1 (GLUT-1), vascular endothelial growth factor (VEGF), microvessel density (MVD) and human telomerase reverse transcriptase (hTERT) proteins expression, based on number of immunohistochemically positive cells (labelling index), were retrospectively studied. In order to assess the prognostic significance of analysed variables in univariate and multivariate Cox analysis, patients were dichotomized based on cut-off points chosen by receiver operating characteristic (ROC) curves. There were 83 males (63.8%) at pT stage 1-2 and 47 (36.1%) at pT stage 3-4, respectively, with median (range) age of 62.8 years (49-77), and median follow-up of 78.5 months (12-148). In 42 (32.3%) men BR was found. In univariate analysis, tumour biological features: PSA ≤ 8 ng/mL (p = 0.006), Ki-67LI ≤ 12.7% (p = 0.015), VEGFLI>11.0% (p = 0.030), and hTERTLI>6.7% (p = 0.016), but not clinicopathological parameters, appeared to be positive prognosticators for BRFS. In the Cox analysis, Ki-67 lost its significance, and clinicopathological parameters appeared to be nonsignificant. The independent negative prognostic factors for BRFS were: PSA > 8.0 ng/mL, (Hazard ratio = 2.75, p = 0.003), GLUT-1 > 19.1% (HR = 2.1, p = 0.032), VEGF≤11.0% (HR = 1, p = 0.024) and hTERT≤6.7% (HR = 1, p = 0.017). High PSA level, and GLUT-1 expression and lower VEGF and nuclear hTERT expression may indicate the great role of hypoxia in BR induction in PCa.

Indexed as

AgedBiomarkers, TumorDisease-Free SurvivalGlucose Transporter Type 1HumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsTelomeraseVascular Endothelial Growth Factor ABiomarkers, TumorGlucose Transporter Type 1Prostate-Specific AntigenTelomeraseVascular Endothelial Growth Factor AVEGFA protein, humanBiochemical failureGLUT-1hTERTProstatic carcinomaPSAVEGF

Identifiers

PMID30989489
PMCPMC7242245
OpenAlexW2936316663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.